Switzerland

F. Hoffmann-La Roche

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Roche Reports Additional Safety Data of Satralizumab in NMOSD

Lead Product(s): Satralizumab

Therapeutic Area: Neurology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 22, 2020

Details:

Pooled data from two pivotal Phase III open-label extension (OLE) studies show satralizumab was well-tolerated as a monotherapy or in combination with baseline immunosuppressive therapy in people with neuromyelitis optica spectrum disorder (NMOSD).

Arvelle Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Arvelle Therapeutics Announces Results of a Randomised Study Showing that Adjunctive Cenobamate Significantly Improved Seizure

Lead Product(s): Cenobamate

Therapeutic Area: Neurology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 21, 2020

Details:

28% of patients receiving cenobamate achieved seizure-freedom (zero seizures) during the study’s maintenance phase, versus 9% receiving placebo1.

F. Hoffmann-La Roche

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

BIO International Convention

Participation Not Confirmed

Update your events

Roche Trial of Ionis Huntington’s Disease Drug Halted After Side Effects

Lead Product(s): Onis-Httrx

Therapeutic Area: Neurology

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 06, 2020

Details:

Cause of the suspension of enrollment was the occurrence of two intrathecal catheter-related infections that weren’t related to the drug.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Product Type

Companies

F. Hoffmann-La Roche

Roche Reports Additional Safety Data of Satralizumab in NMOSD

Arvelle Therapeutics

Arvelle Therapeutics Announces Results of a Randomised Study Showing that Adjunctive Cenobamate Significantly Improved Seizure

F. Hoffmann-La Roche

Roche Trial of Ionis Huntington’s Disease Drug Halted After Side Effects